People & Organization

Our Management

Søren Tulstrup

Søren Tulstrup

President, Chief Executive Officer

Søren Tulstrup has a broad and extensive background as senior executive in the global biopharma industry. Recently, he served as CEO of Vifor Pharma AG (VTX:VIFN), a Glattbrugg, Switzerland-based global pharmaceutical company with a market-leading position within chronic kidney disease, annual sales of approximately USD 1 billion and 2,000 employees. Prior to joining Vifor Pharma, he served as Senior Vice President, Global Franchise Head, MPS at Shire Pharmaceuticals, securing strong market performance of Elaprase (INN: Idursulfase), an enzyme-based treatment of the rare disease Hunter syndrome. Søren Tulstrup has also served as CEO of Santaris Pharma A/S, now part of Roche, a leading clinical stage biopharmaceutical company developing RNA-targeted drugs for various therapeutic areas including cancer and rare genetic diseases. Furthermore, Søren Tulstrup has served in several senior commercial roles within Merck & Co., Inc. and Sandoz Pharma AG (Novartis) and he holds a Master of Science, Economics and Business Administration from Copenhagen Business School. He was born in 1965.

Shareholding: 5000
Share rights (max*): 86,540
ESOPs’ (max*): 66,347

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development

Read more Read less
Dr. Christian Kjellman

Dr. Christian Kjellman

Senior Vice President, Chief Scientific Officer

Christian Kjellman joined Hansa Medical in 2008 after serving at BioInvent AB as Senior Scientist focusing on novel target evaluation and antibody technology. Prior to that, he functioned as Head of Research at the biopharmaceutical development company Cartela AB, mainly focusing on novel drug target evaluation. He has extensive research experience in cell- and molecular biology and as an Assistant Professor in Molecular Genetics at Lund University. Christian Kjellman holds a M.Sc. in Chemical Biology and a Ph.D. in Tumour Immunology from Lund University. He was born in 1967.

Shareholding: -
Share rights (max*): 69,801
ESOP’s: -

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Read more Read less
Max Sakajja

Max Sakajja

Vice President, Corporate Strategy

Max joined Hansa Biopharma in 2017. He has a broad background in corporate development, strategy and finance.  He has previously worked with corporate finance at Swedish Orphan Biovitrum (SOBI) as Director Mergers & Acquisitions and was actively involved in all major transactions such as the acquisition and merger of Swedish Orphan International. Before joining Hansa, Max worked as Global Product and Service Development Manager at Envirotainer, the world leader in secure cold chain solutions for the life science industry, where he played an active role in building new growth-focused corporate strategy and launched a number of industry-first global commercial offerings. Max has also worked as an independent management consultant providing advisory services to the Scandinavian life science industry. Max holds an M.Sc. in Molecular Biotechnology from the Royal Institute of Technology.

 

Read more Read less
Henk Doude van Troostwijk

Henk Doude van Troostwijk

Senior Vice President, Chief Commercial Officer

Henk Doude van Troostwijk has extensive management experience in sales and marketing in the areas of transplantation and orphan drugs. Before joining Hansa Medical in 2016, Henk Doude van Troostwijk served as General Manager of European Commercial Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan disease focused global biopharma company based in the US. Prior to that, he held the position of Business Unit Director Oncology and Transplantation at Genzyme Europe BV. Henk Doude van Troostwijk holds an MBA from Henley Management College at the University of Reading, UK. He was born in 1965.

Shareholding: -
Share rights (max*): 33,817
ESOP's (max): 21,231

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Read more Read less
Donato Spota

Donato Spota

Senior Vice President, Chief Financial Officer

Donato Spota joined Hansa Biopharma in 2019, and brings more than 20 years of pharmaceutical industry experience in international environments, including strategic finance, investor relations and international capital markets transactions to the company. Prior to joining Hansa, Donato Spota served as Chief Financial Officer at Basilea Pharmaceutica AG. He holds a degree in Information Technology from the Swiss BBT (Bundesamt für Berufsbildung und Technologie) and a master’s degree in business administration from the Hochschule für Wirtschaft und Umwelt Nürtingen-Geislingen. He was born 1971.

Shareholding: -
Share rights (max*): 23,434
ESOP’s (max*): 42,642

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Read more Read less
Anne Säfström Lanner

Anne Säfström Lanner

Vice President, Global HR

Anne joined Hansa Biopharma in January 2019, after having served at European Spallation Source (ESS), a joint European multi-disciplinary research facility and at Cellavision, a provider of digital solutions for medical microscopy within hematology. She has held positions both as Head of HR, Head of Resourcing, HR Manager & Deputy Head of HR and has extensive experience from growing start-up international companies. Anne holds a Bachelor of Social Science in Human Resource Management, focusing in organizational development & leadership, from Lund University. Born 1969.

 

Read more Read less
Ulf Wiinberg

Ulf Wiinberg

Chairman of the board since 2016

Ulf Wiinberg is an experienced healthcare industry professional who has served on the boards of several healthcare industry associations. At Wyeth, he has been both President of the Global consumer health care business and President of the European pharma business. He also held the position of CEO of H Lundbeck A/S, a pharmaceutical company specialized in psychiatric and neurological disorders, for several years. Ulf is a non-executive member of the board of Alfa Laval AB, Agenus Inc and at the Belgian pharmaceutical company UCB. He is also chairman of the board of Sigrid Therapeutics AB as well as CEO and chairman of the board of Ulf Wiinberg Consulting & Invest AB. He was born in 1958.

Ulf is chairman of Hansa Biopharma's Remuneration Committee. Independent of Hansa Biopharma and its senior management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 100,000

Read more Read less
Mats Blom

Mats Blom

Member of the board since 2019

Mats Blom has extensive managerial experience and is Chief Financial Officer (CFO) of NorthSea Therapeutics. He has served as CFO of Zealand Pharma A/B, a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mats Blom has held CFO positions at Modus Therapeutics, Active Biotech AB and Anoto Group AB. He has also served as a management consultant at Gemini Consulting and Ernst & Young. Mats Blom holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona.

Mats is member of Hansa Biopharma’s Audit Committee. Independent of Hansa Biopharma and its senior management. Independent of major shareholders of Hansa Biopharma

Shareholding: - 1,000

Read more Read less
Anders Gersel Pedersen

Anders Gersel Pedersen

Member of the board since 2018

Anders Gersel Pedersen has a long experience in the international pharmaceutical industry. Following his degree in medicine and research fellow positions at Copenhagen hospitals, he worked for Eli Lilly for 11 years. In January 2000 he joined H. Lundbeck A/S in Denmark and most recently served as Executive Vice President of the Research & Development organization, responsible for the discovery and development of the product pipeline from pre-clinical activities to post-launch marketing studies. He is a member of the Danish Society of Internal Medicine and serves on the supervisory boards of ALK-Abelló A/S, Bavarian Nordic A/S, and Genmab A/S. Anders Gersel Pedersen received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School. He was born in 1951. 

Anders is Chairman of Hansa Biopharma’s Scientific Committee. Independent of Hansa Biopharma and its senior management. Independent of major shareholders of Hansa Biopharma.

Shareholding: -

Read more Read less
Birgit Stattin Norinder

Birgit Stattin Norinder

Member of the board since 2012

Birgit Stattin Norinder has extensive experience from international pharmaceutical and biotechnology companies in Sweden, the USA and the United Kingdom. She has managed several research and development departments, resulting in a number of novel and approved pharmaceuticals. Amongst many things she has served as CEO and Chairman at Prolifix Ltd., Senior VP Worldwide Product Development, Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division, Glaxo Group Research Ltd. Birgit Stattin Norinder has also held several board and chairman positions of European biotechnology companies. She is a member of the board of AddLife AB and Jettesta AB. Chairman of the Board of Hansa Medical 2014-2016. Birgit Stattin Norinder holds an M.Sc. in Pharmacy from Uppsala University. She was born in 1948.

Birgit Stattin Norinder is member of Hansa Biopharma’s Scientific Committee, and member of the Remuneration Committee. Independent of Hansa Biopharma and its senior management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 39,205

Read more Read less
Eva Nilsagård

Eva Nilsagård

Member of the board since 2019

Eva Nilsagård is currently interim CFO at OptiGroup AB and founder and CEO of Nilsagård Consulting AB. She has served as CFO of Vitrolife and Plastal, Senior Vice President Strategy & Business Development at Volvo Group and held senior positions in finance and business development at Volvo, AstraZeneca and SKF. Eva is a board member and chairman of the audit committee of Addlife, Bufab, Irras and Xbrane Biopharma, and board member of SEK (Swedish Export Credit Company). Eva Nilsagård has more than ten years of experience as a mentor for young female managers with high potential. Eva Nilsagård holds an Executive MBA in Economics and a Bsc in accounting and finance from School of Business, Economics and Law in Gothenburg.

Eva is Chairman of Hansa Biopharma’s Audit Committee. Independent of Hansa Biopharma and its senior management. Independent of major shareholders of Hansa Biopharma.

Shareholding: -

Read more Read less
Andreas Eggert

Andreas Eggert

Member of the board since 2018

Andreas Eggert has more than 20 years of cross-functional leadership experience including commercial operations, launch and portfolio management, brand strategy, market access, and strategic consulting. He served as Senior Group Vice President, Global Product Strategy & Portfolio Development, and Member of the Corporate Management Committee at H. Lundbeck A/S in Denmark, where he was responsible for multiple new product launches and the commercial leadership for shaping the product portfolio and development pipeline. Previously, Andreas served as Vice President & Global Business Manager at Wyeth/Pfizer in the U.S. He held several senior commercial positions for Wyeth in the US, Japan and in Germany. Andreas also was a Management Consultant at A.T. Kearney. Andreas Eggert holds an MBA from Azusa Pacific University. Born in 1967.

Andreas is member of Hansa Biopharma’s Audit Committee and Renumeration Committee. Independent of Hansa Biopharma and its senior management. Independent of major shareholders of Hansa Biopharma.

Shareholding: - 2,500

Read more Read less